Not for human consumption

Survodutide Peptide: Dual Glucagon/GLP-1 Receptor Agonist (BI 456906) | Research Grade

Survodutide research peptide: ≥99% HPLC-verified purity, manufactured in LiveWell’s own Dallas cGMP facility. Survodutide (BI 456906) is a long-acting dual glucagon and GLP-1 receptor agonist from Boehringer Ingelheim and Zealand Pharma, the compound behind the SYNCHRONIZE Phase 3 program published in the New England Journal of Medicine in 2026 and the Phase 2 MASH trial. Supplied as a 10 mg lyophilized vial for in-vitro laboratory research use only.

Coming soon: pre-orders are open now. The first production batch is in the manufacturing and QC queue. Expected ship date: to be announced. Pre-orders ship in the order received once the batch clears third-party testing and the COA is published. Your card is charged at checkout and you can cancel any time before shipment for a full refund.

CAS Number: 2805997-46-8 · Development code: BI 456906
Vial size: 10 mg lyophilized powder
Class: Dual glucagon/GLP-1 receptor agonist, glucagon backbone, C18 diacid acylation, once-weekly exposure profile in published trials
Purity: ≥99% HPLC, third-party tested, COA published on release
Shipping: USA same-day once released (orders before 2pm CT, Mon to Fri) · free over $200

Related: Retatrutide · Tirzepatide · Semaglutide

For laboratory research use only. Not for human or animal consumption. Full details ↓

$ 119.99

Available on backorder

⚠️ Strictly for laboratory research use only. Not for human or animal consumption.

Quantity	Price	Discount
3-5	$ 107.99	10%
6-9	$ 101.99	15%
10+	$ 95.99	20%

Available on backorder

Add $ 200.00 to cart and get free shipping!

Description

Survodutide: Dual Glucagon/GLP-1 Receptor Agonist for Research Use

Survodutide (BI 456906) is a synthetic peptide built on a glucagon backbone and engineered to activate both the glucagon receptor and the GLP-1 receptor. A C18 fatty diacid gives it albumin binding and a once-weekly exposure profile, the same principle used in semaglutide. In published work the GLP-1 component is associated with reduced food intake, while the glucagon component is associated with increased energy expenditure and effects on liver fat, which is why survodutide has been studied in both obesity and metabolic dysfunction-associated steatohepatitis (MASH). LiveWell supplies it as a 10 mg lyophilized vial strictly for in-vitro laboratory research use only.

Chemical Information

Name: Survodutide (BI 456906)
CAS Number: 2805997-46-8
Type: Synthetic acylated dual glucagon/GLP-1 receptor agonist (research grade)
Structure: Glucagon-based sequence with a C18 diacid side chain for albumin binding
Molecular weight: approximately 4232 g/mol
Exposure profile: once-weekly subcutaneous dosing in all published human trials
Vial size: 10 mg lyophilized powder
Purity: ≥99% (HPLC, third-party tested)

Why Researchers Study Survodutide

1. Glucagon receptor contribution. Survodutide is the reference compound for asking what glucagon agonism adds to GLP-1 agonism; the Molecular Metabolism discovery paper documents higher energy expenditure in mice relative to GLP-1 alone.

2. Liver research. The Phase 2 MASH trial (NEJM, 2024) and the SYNCHRONIZE-MASLD Phase 3 (Nature Medicine, 2026) make survodutide one of the most-cited peptides in liver-fat and fibrosis research, with fibrosis effects reported as largely weight independent.

3. Comparative agonist research. Survodutide (glucagon/GLP-1) is studied against Tirzepatide (GIP/GLP-1) and Retatrutide (GIP/GLP-1/glucagon) to separate the contribution of each receptor in cell and animal models.

4. Cardiovascular endpoints. SYNCHRONIZE-CVOT (about 4,935 participants, 5-point MACE) is one of the largest outcome trials in the class and a source of heart-rate and blood-pressure data for the dual-agonist mechanism.

Published Clinical Literature (Research Reference)

For context only. These are results from Boehringer Ingelheim’s investigational drug program. These are results cited from peer-reviewed sources; they are not claims about LiveWell’s research-grade material.

Phase 2 obesity (Lancet Diabetes Endocrinol, 2024): 387 participants, 46 weeks; minus 6.2% to minus 14.9% across 0.6 to 4.8 mg versus minus 2.8% placebo; GI events 75% versus 42%.
Phase 2 MASH (NEJM, 2024): 293 participants, 48 weeks; MASH improvement without worsening of fibrosis in 47% to 62% versus 14% placebo; nausea 66%, vomiting 41%.
SYNCHRONIZE-1, Phase 3 obesity (NEJM, 2026): 725 participants, 76 weeks; minus 12.2% (3.6 mg) and minus 13.0% (6.0 mg) versus minus 5.4% placebo on the treatment-regimen estimand; sponsor efficacy estimand minus 16.6% versus minus 3.2%; GI events 81% to 90% versus 48%.
SYNCHRONIZE-MASLD, Phase 3 (Nat Med, 2026): 216 participants, 48 weeks, 6.0 mg; 30% or greater liver-fat reduction in 84.2% versus 24.3%; body weight minus 12.2% versus minus 1.0%.
Regulatory: FDA Breakthrough Therapy designation for non-cirrhotic MASH (2024), EMA PRIME (2023); SYNCHRONIZE-2 and SYNCHRONIZE-CVOT ongoing; no filing announced as of September 2026.

Storage & Handling

Store lyophilized vials refrigerated at 2 to 8°C, protected from light and heat
Reconstitute with bacteriostatic water; reconstituted material has a shorter storage window
Follow your laboratory’s standard peptide handling protocol

⚠️ Disclaimer: Survodutide research peptide is intended strictly for laboratory research and in-vitro use only. It is not a drug, food, cosmetic, or dietary supplement. This product has not been evaluated or approved by the FDA and is not for human or veterinary use. No therapeutic, weight-management or metabolic-health claims are made or implied.

Regulatory status: Survodutide is an investigational compound in clinical development by Boehringer Ingelheim and is not approved for any use in any country as of September 2026. The research-grade material sold by LiveWell is not a drug product: it is not manufactured, compounded, or approved for pharmaceutical use, and is strictly for in-vitro laboratory research. Nothing on this page constitutes medical advice.

Survodutide research reference: View the SYNCHRONIZE-1 Phase 3 trial on PubMed

Pre-Order Survodutide Research Peptide: cGMP Manufactured in Dallas, TX

Qualified researchers can pre-order Survodutide directly from the manufacturer. LiveWell Peptides produces research-grade Survodutide in our cGMP facility in Dallas, Texas. Every vial is third-party tested to verify ≥99% HPLC purity, amino acid identity by mass spectrometry, and endotoxin limits by LAL testing, and the batch COA is published on our COA page on the day of release. Pre-orders ship in the order received (expected ship date: to be announced); once released, US orders placed before 2pm CT (Mon to Fri) ship same-day in cold-chain packaging, with free domestic shipping over $200. International shipping is available.

Why Researchers Source Survodutide from LiveWell

Documentation, not claims. Every batch ships with a verified COA confirming identity and purity, published on our COA page rather than supplied only on request.

Four-point analytical testing. HPLC for purity, mass spectrometry for amino acid identity, and LAL testing for endotoxins, with independent third-party verification on top of in-house quality control.

US manufacturing and cold-chain logistics. Orders ship from our Dallas, Texas facility, with international shipping to Colombia, Mexico, Brazil, Argentina, Chile and Peru.

Related research compounds

Retatrutide (Triple GLP-1/GIP/Glucagon) · Tirzepatide (Dual GIP/GLP-1) · Semaglutide (GLP-1) · Eloralintide (Amylin) · Bacteriostatic Water · Certificates of Analysis

Research literature

Selected peer-reviewed sources for research reference:

Zimmermann T et al. (2022). BI 456906: Discovery and preclinical pharmacology of a novel GCG/GLP-1 receptor dual agonist with robust anti-obesity efficacy. Mol Metab. PMID: 36356832
le Roux CW et al. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. PMID: 38330987
Sanyal AJ et al. (2024). A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. PMID: 38847460
le Roux CW et al. (2026). Survodutide in adults with obesity or overweight (SYNCHRONIZE-1). N Engl J Med. PMID: 42253238
Kaplan LM et al. (2026). Survodutide in metabolic dysfunction-associated steatotic liver disease (SYNCHRONIZE-MASLD). Nat Med. PMID: 42208956

References are provided for research reference only. Inclusion of literature does not constitute a recommendation, endorsement, or claim for any specific use of LiveWell Peptides products. Products are sold for laboratory and research use only and are not intended for human consumption, injection, topical application, or any other administration to the human body.

Frequently Asked Questions

What is Survodutide?

Survodutide (BI 456906, CAS 2805997-46-8) is a long-acting peptide that activates both the glucagon receptor and the GLP-1 receptor, developed by Boehringer Ingelheim and Zealand Pharma. We supply it as a 10 mg lyophilized vial strictly for in-vitro laboratory research.

How does Survodutide differ from Semaglutide?

Semaglutide activates the GLP-1 receptor only. Survodutide adds glucagon receptor agonism, which in the published discovery paper was associated with higher energy expenditure in mice. Both use fatty-acid acylation for once-weekly exposure.

How does Survodutide differ from Tirzepatide and Retatrutide?

Tirzepatide pairs GLP-1 with GIP, and Retatrutide is a triple GLP-1/GIP/glucagon agonist. Survodutide pairs GLP-1 with glucagon and has no GIP activity. No head-to-head trial has been published, so comparisons rely on separate trials.

What did the Phase 3 SYNCHRONIZE-1 trial report?

In NEJM (2026), 725 participants over 76 weeks showed body-weight change of minus 12.2% (3.6 mg) and minus 13.0% (6.0 mg) versus minus 5.4% placebo on the primary estimand; the sponsor efficacy estimand was minus 16.6% versus minus 3.2%. Gastrointestinal events were the main adverse events. Cited for research reference only.

Why is Survodutide studied in liver research?

The Phase 2 MASH trial (NEJM, 2024) reported MASH improvement without fibrosis worsening in 47% to 62% of participants versus 14% on placebo, and the Phase 3 SYNCHRONIZE-MASLD study reported a 30% or greater liver-fat reduction in 84% of participants. These are published findings, not product claims.

What purity is LiveWell Survodutide, and is a COA included?

Every batch is third-party tested at ≥99% purity by HPLC, with mass spectrometry identity confirmation and LAL endotoxin testing. The batch Certificate of Analysis is published on our COA page the day the pre-order batch is released.

How should Survodutide be stored and reconstituted?

Store the lyophilized vial refrigerated at 2 to 8°C, protected from light and heat. Reconstitute with bacteriostatic water; reconstituted material has a considerably shorter storage window.

How do pre-orders work, and when will it ship?

Pre-orders are charged at checkout and ship in the order received once the first batch clears third-party testing and the COA is published. You will receive tracking the day it ships. If you change your mind before shipment, contact us for a full refund.

Is Survodutide a drug or supplement?

No. Survodutide is an investigational compound that has not been approved by the FDA or any regulator. The research-grade material sold by LiveWell is not a drug product, dietary supplement, food or cosmetic, and it is not intended for human or animal consumption.

Péptidos de investigación disponibles con envío internacional. Survodutida de grado de investigación fabricada en instalaciones cGMP en Dallas, Texas. Certificado de análisis incluido con cada lote. Solo para uso en investigación.

Research Use Only Disclaimer: This product is sold strictly for in vitro laboratory research. NOT for human or animal consumption. LiveWell Peptides makes no medical claims.